To resolve these contradictions, future research should focus on quantifying the relative activity of oncogenic versus tumor‐suppressive LIF and LIFR pathways, thereby identifying potential therapeutic contexts in which LIF blockade or activation may be beneficial in GC treatment. The gene discussed is LIFR; the disease is neoplasm.